Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Evidence for complex binding profiles and species differences at the translocator protein (TSPO) (18 kDa).

Scarf AM, Luus C, Da Pozzo E, Selleri S, Guarino C, Martini C, Ittner LM, Kassiou M.

Curr Mol Med. 2012 May;12(4):488-93.

PMID:
22348617
2.
3.

Structural requirements to obtain highly potent and selective 18 kDa Translocator Protein (TSPO) Ligands.

Taliani S, Pugliesi I, Da Settimo F.

Curr Top Med Chem. 2011;11(7):860-86. Review.

PMID:
21291396
4.

The nitric oxide donor sodium nitroprusside requires the 18 kDa Translocator Protein to induce cell death.

Shargorodsky L, Veenman L, Caballero B, Pe'er Y, Leschiner S, Bode J, Gavish M.

Apoptosis. 2012 Jul;17(7):647-65. doi: 10.1007/s10495-012-0725-2.

PMID:
22544277
5.
6.

Translocator protein as a promising target for novel anxiolytics.

Costa B, Da Pozzo E, Martini C.

Curr Top Med Chem. 2012;12(4):270-85. Review.

PMID:
22204481
7.

PK 11195 differentially affects cell survival in human wild-type and 18 kDa translocator protein-silenced ADF astrocytoma cells.

Chelli B, Salvetti A, Da Pozzo E, Rechichi M, Spinetti F, Rossi L, Costa B, Lena A, Rainaldi G, Scatena F, Vanacore R, Gremigni V, Martini C.

J Cell Biochem. 2008 Oct 15;105(3):712-23. doi: 10.1002/jcb.21865.

PMID:
18668527
8.
9.

CoCl(2) induces apoptosis via the 18 kDa translocator protein in U118MG human glioblastoma cells.

Zeno S, Zaaroor M, Leschiner S, Veenman L, Gavish M.

Biochemistry. 2009 Jun 2;48(21):4652-61. doi: 10.1021/bi900064t.

PMID:
19358520
10.

Translocator protein 18 kDa is involved in the regulation of reactive gliosis.

Veiga S, Carrero P, Pernia O, Azcoitia I, Garcia-Segura LM.

Glia. 2007 Nov 1;55(14):1426-36.

PMID:
17674368
11.

Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo.

Sakai M, Ferraz-de-Paula V, Pinheiro ML, Ribeiro A, Quinteiro-Filho WM, Rone MB, Martinez-Arguelles DB, Dagli ML, Papadopoulos V, Palermo-Neto J.

Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8. doi: 10.1016/j.ejphar.2009.09.036. Epub 2009 Sep 24.

PMID:
19782064
13.

Translocator protein ligands as promising therapeutic tools for anxiety disorders.

Taliani S, Da Settimo F, Da Pozzo E, Chelli B, Martini C.

Curr Med Chem. 2009;16(26):3359-80. Epub 2009 Sep 1. Review.

PMID:
19548867
14.

Distribution, pharmacological characterization and function of the 18 kDa translocator protein in rat small intestine.

Ostuni MA, Péranzi G, Ducroc RA, Fasseu M, Vidic B, Dumont J, Papadopoulos V, Lacapere JJ.

Biol Cell. 2009 Jul 31;101(10):573-86. doi: 10.1042/BC20080231.

PMID:
19392661
15.

Intracellular cholesterol changes induced by translocator protein (18 kDa) TSPO/PBR ligands.

Falchi AM, Battetta B, Sanna F, Piludu M, Sogos V, Serra M, Melis M, Putzolu M, Diaz G.

Neuropharmacology. 2007 Aug;53(2):318-29. Epub 2007 Jun 2.

PMID:
17631921
16.
17.

DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization.

James ML, Fulton RR, Vercoullie J, Henderson DJ, Garreau L, Chalon S, Dolle F, Costa B, Guilloteau D, Kassiou M.

J Nucl Med. 2008 May;49(5):814-22. doi: 10.2967/jnumed.107.046151. Epub 2008 Apr 15. Erratum in: J Nucl Med. 2008 Jul;49(7):1096. Selleri, Silvia [corrected to Costa, Barbara].

18.

The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production.

Danovich L, Veenman L, Leschiner S, Lahav M, Shuster V, Weizman A, Gavish M.

Eur Neuropsychopharmacol. 2008 Jan;18(1):24-33. Epub 2007 Jun 11.

PMID:
17561380
19.

Novel irreversible fluorescent probes targeting the 18 kDa translocator protein: synthesis and biological characterization.

Taliani S, Da Pozzo E, Bellandi M, Bendinelli S, Pugliesi I, Simorini F, La Motta C, Salerno S, Marini AM, Da Settimo F, Cosimelli B, Greco G, Novellino E, Martini C.

J Med Chem. 2010 May 27;53(10):4085-93. doi: 10.1021/jm100100q.

PMID:
20438080
20.

Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma.

Papadopoulos V, Lecanu L.

Exp Neurol. 2009 Sep;219(1):53-7. doi: 10.1016/j.expneurol.2009.04.016. Epub 2009 May 4. Review.

Items per page

Supplemental Content

Write to the Help Desk